Delving into the Latest Updates on HEC-648 with Synapse

Overview

Basic Info

Drug Type

Monoclonal antibody

Synonyms

HEC 648, HEC648

Target

GTP-binding proteins

Action

inhibitors

Mechanism

GTP-binding proteins inhibitors(GTP-binding proteins inhibitors)

Therapeutic Areas

Infectious Diseases

Active Indication

Henipavirus Infections

Inactive Indication-

Originator Organization

YiChang HEC ChangJiang Pharmaceutical Co., Ltd.

Active Organization

Wuhan Institute of Virologychinese AcademyShenzhen Gebijia Molecular Drug Innovation Center Co., Ltd.

YiChang HEC ChangJiang Pharmaceutical Co., Ltd.

Inactive Organization-

License Organization-

Drug Highest PhasePhase 1

First Approval Date-

Regulation-

Login to view timeline

主要目的： 1）评价 HEC-648 注射液在健康试验参与者中单次和多次给药的安全性和耐受性。次要目的： 1）评价 HEC-648 注射液在健康试验参与者中单次和多次给药的药代动力学特征。 2）评价 HEC-648 注射液在健康试验参与者中单次和多次给药的免疫原性。 3）评价 HEC-648 注射液在健康试验参与者中单次和多次给药后的药效学特征。

[Translation]

Primary Objectives: 1) To evaluate the safety and tolerability of HEC-648 injection after single and multiple administrations in healthy trial participants. Secondary Objectives: 1) To evaluate the pharmacokinetic characteristics of HEC-648 injection after single and multiple administrations in healthy trial participants. 2) To evaluate the immunogenicity of HEC-648 injection after single and multiple administrations in healthy trial participants. 3) To evaluate the pharmacodynamic characteristics of HEC-648 injection after single and multiple administrations in healthy trial participants.

Start Date21 Sep 2026

Sponsor / Collaborator

Wuhan Institute of Virologychinese Academy

[+2]

100 Clinical Results associated with HEC-648

Login to view more data

100 Translational Medicine associated with HEC-648

Login to view more data

100 Patents (Medical) associated with HEC-648

Login to view more data

100 Deals associated with HEC-648

Login to view more data

R&D Status

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Henipavirus Infections	Phase 1	China	YiChang HEC ChangJiang Pharmaceutical Co., Ltd.	15 Sep 2026

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Login to view more data

Translational Medicine

Boost your research with our translational medicine data.

login

or

view full example data

Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.

login

or

view full example data

Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.

login

or

view full example data

Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.

login

or

view full example data

Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.

login

or

view full example data

Accelerate your research with the latest regulatory approval information.

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

login

or

view full example data